ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution: A Report of the American College of Cardiology Foundation Clinical Quality Committee.
Circulation. 2011 Aug 15;
Authors: Holmes DR, Becker JA, Granger CB, Limacher MC, Page RL, Sila C
PMID: 21844072 [PubMed - as supplied by publisher]
Link to Article at PubMedRenal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury.
Circulation. 2011 Aug 15;
Authors: Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G,
Background- The RenalGuard System, which creates high urine output and fluid balancing, may be beneficial in preventing contrast-induced acute kidney injury. Methods and Results- The Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II) trial is a randomized, multicenter, investigator-driven trial addressing the prevention of contrast-induced acute kidney injury in high-risk patients. Patients with an estimated glomerular filtration rate ?30 mL · min(-1) · 1.73 m(-2) and/or a risk score ?11 were randomly assigned to sodium bicarbonate solution and N-acetylcysteine (control group) or hydration with saline and N-acetylcysteine controlled by the RenalGuard System and furosemide (RenalGuard group). The primary end point was an increase of ?0.3 mg/dL in the serum creatinine concentration at 48 hours after the procedure. The secondary end points included serum cystatin C kinetics and rate of in-hospital dialysis. Contrast-induced acute kidney injury occurred in 16 of 146 patients in the RenalGuard group (11%) and in 30 of 146 patients in the control group (20.5%; odds ratio, 0.47; 95% confidence interval, 0.24 to 0.92). There were 142 patients (48.5%) with an estimated glomerular filtration rate ?30 mL · min(-1) · 1.73 and 149 patients (51.5%) with only a risk score ?11. Subgroup analysis according to inclusion criteria showed a similarly lower risk of adverse events (estimated glomerular filtration rate ?30 mL · min(-1) · 1.73 m(-2): odds ratio, 0.44; risk score ?11: odds ratio, 0.45; P for interaction=0.97). Changes in cystatin C at 24 hours (0.02±0.32 versus -0.08±0.26; P=0.002) and 48 hours (0.12±0.42 versus 0.03±0.31; P=0.001) and the rate of in-hospital dialysis (4.1% versus 0.7%; P=0.056) were higher in the control group. Conclusion- RenalGuard therapy is superior to sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients. Clinical Trial Registration- URL: http://www.clinicaltrial.gov. Unique identifier: NCT01098032.
PMID: 21844075 [PubMed - as supplied by publisher]
Link to Article at PubMedHospital systems for the detection and prevention of adverse drug events.
Clin Pharmacol Ther. 2011 Jun;89(6):779-81
Authors: Cheng CM
In its 2006 report "Preventing Medication Errors," the Institute of Medicine (IOM) estimated that more than 1.5 million preventable adverse drug events (ADEs) occur annually in the United States. Many organizations, including the IOM, the Institute for Safe Medication Practices, the US Food and Drug Administration, and the Leap Frog Group for Patient Safety have advocated the implementation of technologies to reduce ADEs, particularly in the hospital setting. Many technologies have emerged in recent years to reduce ADEs at various points in the medication use process; however, interfacing some of these key technologies with existing hospital systems poses significant challenges.
PMID: 21593752 [PubMed - indexed for MEDLINE]
Link to Article at PubMedNew trends in infective endocarditis.
Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 4:22-35
Authors: Fariñas MC, Llinares P, Almirante B, Barberán J, de Dios Colmenero J, Garau J, Gudiol F, Hernández Quero J, Mensa J, Montejo M, Pachón J, Rodríguez-Baño J, Sánchez-García M
The present article is an update of the literature on endocarditis. A multidisciplinary group of Spanish physicians with an interest in cardiac infections selected the most important papers produced lately in the field. Two of the members of the group discussed the content of each of the selected papers, with a critical review by others members of the panel. After a review of the state of the art papers from the fields of epidemiology, new causative microorganisms (bacterial and fungal), clinical findings including those in special patients, laboratory diagnosis, prognostic factors, nosocomial endocarditis, prophylaxis, new drugs and guidelines for antibiotic treatment were discussed by the group.
PMID: 21458717 [PubMed - indexed for MEDLINE]
Link to Article at PubMedUpdate on fungemia in oncology and hematology.
Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 4:42-7
Authors: Carreras E, Vázquez L, Rodríguez Tudela JL, Pahisa A, Azanza JR, Rovira M, de la Cámara R
The present article is an update of the literature on fungemia in onco-hematologic patients. A multidisciplinary group of Spanish physicians with an interest in this field selected the most important papers published lately. Papers from the fields of epidemiology, risk factors, pathogenesis, diagnosis, outcome, prevention and treatment are discussed. Important aspects of these studies include the assessment of different strategies in the management of fever in neutropenic patients. Moreover, early identification of patients at risk of fungal infections, as well as identification of patients at risk for fluconazole-resistant strains are topics of increasing interest.
PMID: 21458719 [PubMed - indexed for MEDLINE]
Link to Article at PubMedUpdate on bacteraemia in oncology and hematology.
Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 4:48-53
Authors: Fortún J, Sanz MÁ, Madero L, López J, de la Torre J, Jarque I, Vallejo C
The present article is an update of the literature on bacteraemia in onco-hematologic patients. A multidisciplinary group of Spanish physicians with an interest in this field selected the most important papers published recently. Papers from the fields of basic science, epidemiology, causative microorganisms and clinical syndromes are discussed. Important aspects of these studies include the assessment of different strategies in the management of fever in neutropenic patients and the validation of specific scores. Moreover, early identification of patients at risk of bacterial and of multi-drug resistant infections is a topic of increasing interest.
PMID: 21458720 [PubMed - indexed for MEDLINE]
Link to Article at PubMed